nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

23.01.2020 | Original Article

Influx rate constant of ¹⁸F-FDG increases in metastatic lymph nodes of non-small cell lung cancer patients

verfasst von: Min Yang, Zhong Lin, Zeqing Xu, Dan Li, Weize Lv, Shuai Yang, Ye Liu, Ying Cao, Qingdong Cao, Hongjun Jin

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Primary tumor (PT) and metastatic lymph node (MLN) status have a great influence on diagnosis and treatment of lung cancer. Our main purpose was to investigate the imaging characteristics of PT or MLN by applying the ¹⁸F-FDG PET dynamic modeling approach for non-small cell lung cancer (NSCLC).

Methods

Dynamic ¹⁸F-FDG PET scans were performed for 76 lung cancer patients, and 62 NSCLC cases were finally included in this study: 37 with newly diagnosed early and locally advanced lung cancer without distant metastases (group M0) and 25 metastatic lung cancer (group M1). Patlak graphic analysis (K_i calculation) based on the dynamic modeling and SUV analysis from conventional static data were performed.

Results

For PT, both K_i^PT (0.050 ± 0.005 vs 0.026 ± 0.004 min⁻¹, p < 0.001) and SUV^PT (8.41 ± 0.64 vs 5.23 ± 0.73, p < 0.01) showed significant higher values in group M1 than M0. For MLN, K_i^MLN showed significant higher values in M1 than M0 (0.033 ± 0.005 vs 0.016 ± 0.003 min⁻¹, p < 0.01), while no significant differences were found for SUV^MLN between M0 and M1 (4.22 ± 0.49 vs 5.57 ± 0.59, p > 0.05). Both SUV ^PT and K_i^PT showed significant high values in squamous cell carcinoma than adenocarcinoma, but neither SUV^PT nor K_i^PT showed significant differences between EGFR mutants versus wild types. The overall Spearman analysis for SUV and K_i from different groups showed variable correlation (r = 0.46–0.94).

Conclusion

The dynamic modeling for MLN (K_i^MLN) showed more sensitive than the static analysis (SUV) to detect metastatic lymph nodes in NSCLC, although both methods were sensitive for PT. This methodology of non-invasive imaging may become an important tool to evaluate MLN and PT status for patients who cannot undergo histological examination.

Clinical trial registration

The clinical trial registration number is NCT03679936 (http://www.clinicaltrials.gov/).

Nur mit Berechtigung zugänglich

May M. Statistics: attacking an epidemic. Nature. 2014;509:S50–1. https://doi.org/10.1038/509S50a.CrossRefPubMed

Lortet-Tieulent J, Soerjomataram I, Ferlay J, Rutherford M, Weiderpass E, Bray F. International trends in lung cancer incidence by histological subtype: adenocarcinoma stabilizing in men but still increasing in women. Lung Cancer (Amsterdam, Netherlands). 2014;84:13–22. https://doi.org/10.1016/j.lungcan.2014.01.009.CrossRef

Strauss LG. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med. 1996;23:1409–15.CrossRef

Som P, Atkins HL, Bandoypadhyay D, Fowler JS, MacGregor RR, Matsui K, et al. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection. J Nucl Med : official publication, Society of Nuclear Medicine. 1980;21:670–5.

Hamberg LM, Hunter GJ, Alpert NM, Choi NC, Babich JW, Fischman AJ. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med : official publication, Society of Nuclear Medicine. 1994;35:1308–12.

Huang SC. Anatomy of SUV. Standardized uptake value. Nucl Med Biol. 2000;27:643–6.CrossRef

Keyes JW Jr. SUV: standard uptake or silly useless value? J Nucl Med : official publication, Society of Nuclear Medicine. 1995;36:1836–9.

Sugawara Y, Zasadny KR, Neuhoff AW, Wahl RL. Reevaluation of the standardized uptake value for FDG: variations with body weight and methods for correction. Radiology. 1999;213:521–5. https://doi.org/10.1148/radiology.213.2.r99nv37521.CrossRefPubMed

Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology. 1993;189:847–50. https://doi.org/10.1148/radiology.189.3.8234714.CrossRefPubMed

10.

Laffon E, de Clermont H, Begueret H, Vernejoux JM, Thumerel M, Marthan R, et al. Assessment of dual-time-point 18F-FDG-PET imaging for pulmonary lesions. Nucl Med Commun. 2009;30:455–61. https://doi.org/10.1097/MNM.0b013e32832bdcac.CrossRefPubMed

11.

Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab : official journal of the International Society of Cerebral Blood Flow and Metabolism. 1983;3:1–7. https://doi.org/10.1038/jcbfm.1983.1.CrossRef

12.

Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol. 1979;6:371–88. https://doi.org/10.1002/ana.410060502.CrossRefPubMed

13.

Gambhir SS, Schwaiger M, Huang SC, Krivokapich J, Schelbert HR, Nienaber CA, et al. Simple noninvasive quantification method for measuring myocardial glucose utilization in humans employing positron emission tomography and fluorine-18 deoxyglucose. J Nucl Med : official publication, Society of Nuclear Medicine. 1989;30:359–66.

14.

Chen K, Bandy D, Reiman E, Huang SC, Lawson M, Feng D, et al. Noninvasive quantification of the cerebral metabolic rate for glucose using positron emission tomography, 18F-fluoro-2-deoxyglucose, the Patlak method, and an image-derived input function. J Cereb Blood Flow Metab : official journal of the International Society of Cerebral Blood Flow and Metabolism. 1998;18:716–23. https://doi.org/10.1097/00004647-199807000-00002.CrossRef

15.

van der Weerdt AP, Klein LJ, Boellaard R, Visser CA, Visser FC, Lammertsma AA. Image-derived input functions for determination of MRGlu in cardiac (18)F-FDG PET scans. J Nucl Med : official publication, Society of Nuclear Medicine. 2001;42:1622–9.

16.

Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The eighth edition lung cancer stage classification. Chest. 2017;151:193–203. https://doi.org/10.1016/j.chest.2016.10.010.CrossRef

17.

Boellaard R. Standards for PET image acquisition and quantitative data analysis. J Nucl Med : official publication, Society of Nuclear Medicine. 2009;50(Suppl 1):11s–20s. https://doi.org/10.2967/jnumed.108.057182.CrossRef

18.

Boellaard R, Oyen WJ, Hoekstra CJ, Hoekstra OS, Visser EP, Willemsen AT, et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging. 2008;35:2320–33. https://doi.org/10.1007/s00259-008-0874-2.CrossRefPubMed

19.

Boellaard R, van Lingen A, Lammertsma AA. Experimental and clinical evaluation of iterative reconstruction (OSEM) in dynamic PET: quantitative characteristics and effects on kinetic modeling. J Nucl Med : official publication, Society of Nuclear Medicine. 2001;42:808–17.

20.

Hudson HM, Larkin RS. Accelerated image reconstruction using ordered subsets of projection data. IEEE Trans Med Imaging. 1994;13:601–9. https://doi.org/10.1109/42.363108.CrossRef

21.

Freedman NM, Sundaram SK, Kurdziel K, Carrasquillo JA, Whatley M, Carson JM, et al. Comparison of SUV and Patlak slope for monitoring of cancer therapy using serial PET scans. Eur J Nucl Med Mol Imaging. 2003;30:46–53. https://doi.org/10.1007/s00259-002-0981-4.CrossRefPubMed

22.

Vieira S, Corrente JE. Statistical methods for assessing agreement between double readings of clinical measurements. J Appl Oral Sci : revista FOB. 2011;19:488–92.CrossRef

23.

van Baardwijk A, Dooms C, van Suylen RJ, Verbeken E, Hochstenbag M, Dehing-Oberije C, et al. The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer. Eur J Cancer (Oxford, England : 1990). 2007;43:1392–8. https://doi.org/10.1016/j.ejca.2007.03.027.CrossRef

24.

Chung JK, Lee YJ, Kim SK, Jeong JM, Lee DS, Lee MC. Comparison of [18F]fluorodeoxyglucose uptake with glucose transporter-1 expression and proliferation rate in human glioma and non-small-cell lung cancer. Nucl Med Commun. 2004;25:11–7.CrossRef

25.

Higashi K, Ueda Y, Sakurai A, Mingwang X, Xu L, Murakami M, et al. Correlation of Glut-1 glucose transporter expression with [(18)F]FDG uptake in non-small cell lung cancer. Eur J Nucl Med. 2000;27:1778–85. https://doi.org/10.1007/s002590000367.CrossRefPubMed

26.

van Berkel A, Vriens D, Visser EP, Janssen MJR, Gotthardt M, Hermus A, et al. Metabolic subtyping of pheochromocytoma and paraganglioma by (18)F-FDG pharmacokinetics using dynamic PET/CT scanning. J Nucl Med : official publication, Society of Nuclear Medicine. 2019;60:745–51. https://doi.org/10.2967/jnumed.118.216796.CrossRef

27.

de Geus-Oei LF, van Krieken JH, Aliredjo RP, Krabbe PF, Frielink C, Verhagen AF, et al. Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 2007;55:79–87. https://doi.org/10.1016/j.lungcan.2006.08.018.CrossRef

28.

Weber WA, Ziegler SI, Thodtmann R, Hanauske AR, Schwaiger M. Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med : official publication, Society of Nuclear Medicine. 1999;40:1771–7.

29.

Minn H, Leskinen-Kallio S, Lindholm P, Bergman J, Ruotsalainen U, Teras M, et al. [18F]fluorodeoxyglucose uptake in tumors: kinetic vs. steady-state methods with reference to plasma insulin. J Comput Assist Tomogr. 1993;17:115–23.CrossRef

30.

Minn H, Zasadny KR, Quint LE, Wahl RL. Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET. Radiology. 1995;196:167–73. https://doi.org/10.1148/radiology.196.1.7784562.CrossRefPubMed

31.

Lodge MA, Lucas JD, Marsden PK, Cronin BF, O'Doherty MJ, Smith MA. A PET study of 18FDG uptake in soft tissue masses. Eur J Nucl Med. 1999;26:22–30.CrossRef

32.

Gallagher BM, Fowler JS, Gutterson NI, MacGregor RR, Wan CN, Wolf AP. Metabolic trapping as a principle of oradiopharmaceutical design: some factors resposible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose. J Nucl Med : official publication, Society of Nuclear Medicine. 1978;19:1154–61.

33.

Hoekstra CJ, Paglianiti I, Hoekstra OS, Smit EF, Postmus PE, Teule GJ, et al. Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography: an overview of different analytical methods. Eur J Nucl Med. 2000;27:731–43.CrossRef

34.

Sundaram SK, Freedman NM, Carrasquillo JA, Carson JM, Whatley M, Libutti SK, et al. Simplified kinetic analysis of tumor 18F-FDG uptake: a dynamic approach. J Nucl Med : official publication, Society of Nuclear Medicine. 2004;45:1328–33.

35.

McDermott GM, Welch A, Staff RT, Gilbert FJ, Schweiger L, Semple SI, et al. Monitoring primary breast cancer throughout chemotherapy using FDG-PET. Breast Cancer Res Treat. 2007;102:75–84. https://doi.org/10.1007/s10549-006-9316-7.CrossRefPubMed

36.

Sun X, Xiao Z, Chen G, Han Z, Liu Y, Zhang C, et al. A PET imaging approach for determining EGFR mutation status for improved lung cancer patient management. Sci Transl Med. 2018;10. https://doi.org/10.1126/scitranslmed.aan8840.

37.

Choi YJ, Cho BC, Jeong YH, Seo HJ, Kim HJ, Cho A, et al. Correlation between (18)f-fluorodeoxyglucose uptake and epidermal growth factor receptor mutations in advanced lung cancer. Nucl Med Mol Imaging. 2012;46:169–75. https://doi.org/10.1007/s13139-012-0142-z.CrossRefPubMedPubMedCentral

38.

Huang CT, Yen RF, Cheng MF, Hsu YC, Wei PF, Tsai YJ, et al. Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma. Medical Oncology (Northwood, London, England). 2010;27:9–15. https://doi.org/10.1007/s12032-008-9160-1.CrossRef

Titel: Influx rate constant of 18F-FDG increases in metastatic lymph nodes of non-small cell lung cancer patients
verfasst von: Min Yang
Zhong Lin
Zeqing Xu
Dan Li
Weize Lv
Shuai Yang
Ye Liu
Ying Cao
Qingdong Cao
Hongjun Jin
Publikationsdatum: 23.01.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 5/2020
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-020-04682-5

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Clinical trial registration

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2020

McCune-Albright syndrome confirmed by 99mTc-MDP

Lymphoscintigraphy and sentinel lymph node biopsy in vulvar carcinoma: update from a European expert panel

Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2

Diagnostic performance of 18F-FDG PET/CT in patients with spinal infection: a systematic review and a bivariate meta-analysis

Correlation between combining 18F–FDG PET/CT metabolic parameters and other clinical features and ALK or ROS1 fusion in patients with non-small-cell lung cancer

The feasibility of quantitative parameters of lymphoscintigraphy without significant dermal backflow for the evaluation of lymphedema in post-operative patients with breast cancer